New Triple-Threat attack on Tough-to-Treat colon cancer
NCT ID NCT06412198
Summary
This study is testing whether a combination of three drugs—adagrasib, cetuximab, and cemiplimab—can help control metastatic colorectal cancer that has a specific genetic change called a KRAS G12C mutation. The trial aims to see how well the treatment works and how safe it is for patients whose cancer has worsened after at least one prior round of chemotherapy. It will enroll about 31 adults with this specific type of advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital Cancer Center
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.